S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Cameco Stock is the Real Deal Uranium Play
pixel
3 Overdone Selloffs Offering a Second Chance
3 Value Stocks in Focus as Rotation Continues
2 Undervalued Consumer Stocks For Your Watchlist
pixel
Kroger Stock Presents Investors With a Crisis of Conviction
Shares slip in Asia after bond yield spike hits Wall St
Reading International Stock is an Under the Radar Dual Reopening Play
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Cameco Stock is the Real Deal Uranium Play
pixel
3 Overdone Selloffs Offering a Second Chance
3 Value Stocks in Focus as Rotation Continues
2 Undervalued Consumer Stocks For Your Watchlist
pixel
Kroger Stock Presents Investors With a Crisis of Conviction
Shares slip in Asia after bond yield spike hits Wall St
Reading International Stock is an Under the Radar Dual Reopening Play
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Cameco Stock is the Real Deal Uranium Play
pixel
3 Overdone Selloffs Offering a Second Chance
3 Value Stocks in Focus as Rotation Continues
2 Undervalued Consumer Stocks For Your Watchlist
pixel
Kroger Stock Presents Investors With a Crisis of Conviction
Shares slip in Asia after bond yield spike hits Wall St
Reading International Stock is an Under the Radar Dual Reopening Play
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Cameco Stock is the Real Deal Uranium Play
pixel
3 Overdone Selloffs Offering a Second Chance
3 Value Stocks in Focus as Rotation Continues
2 Undervalued Consumer Stocks For Your Watchlist
pixel
Kroger Stock Presents Investors With a Crisis of Conviction
Shares slip in Asia after bond yield spike hits Wall St
Reading International Stock is an Under the Radar Dual Reopening Play
pixel
Log in
NASDAQ:FUSN

Fusion Pharmaceuticals Stock Forecast, Price & News

$11.25
-0.18 (-1.57 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.75
Now: $11.25▼
$11.41
50-Day Range
$11.26
MA: $12.01▼
$13.09
52-Week Range
$10.51
Now: $11.25▼
$19.00
Volume32,622 shs
Average Volume53,121 shs
Market Capitalization$469.42 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Fusion Pharmaceuticals logo

Headlines

Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
March 2, 2021 |  finance.yahoo.com
Fusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care Conference
February 23, 2021 |  finance.yahoo.com
Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., to Board of Directors
February 11, 2021 |  finance.yahoo.com
Fusion Pharmaceuticals (NASDAQ:FUSN) Is In A Good Position To Deliver On Growth Plans
January 25, 2021 |  finance.yahoo.com
IPO Lockup Expiration Alert: Fusion Pharmaceuticals (FUSN)
December 22, 2020 |  rttnews.com
TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope
December 16, 2020 |  finance.yahoo.com
Is FUSN A Good Stock To Buy Now?
December 10, 2020 |  finance.yahoo.com
Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors
December 10, 2020 |  finance.yahoo.com
What Is The Ownership Structure Like For Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)?
November 26, 2020 |  finance.yahoo.com
Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
November 12, 2020 |  finance.yahoo.com
Big things are Poppin' at Bad Monkey Popcorn: Champlain Financial acquires rapidly expanding Canadian popcorn manufacturer
November 12, 2020 |  finance.yahoo.com
Fusion Pharmaceuticals EPS misses by $0.04
November 10, 2020 |  seekingalpha.com
Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
November 10, 2020 |  finance.yahoo.com
Fusion Pharmaceuticals Inc. Common Shares (FUSN)
November 2, 2020 |  nasdaq.com
Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors
November 2, 2020 |  finance.yahoo.com
Orion Mine Finance Provides Update of its Ownership of Common Shares of Doré Copper Mining Corp.
October 27, 2020 |  finance.yahoo.com
Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer
September 29, 2020 |  prnewswire.com
Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
September 10, 2020 |  finance.yahoo.com
Fusion Pharmaceuticals EPS of -$18.91
August 11, 2020 |  seekingalpha.com
Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
August 11, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FUSN
Previous Symbol
CUSIPN/A
CIKN/A
Webfusionpharma.com
Phone289-799-0891
Employees37
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio55.92
Quick Ratio55.92

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-16,190,000.00
Net MarginsN/A
Return on Equity-26.14%
Return on Assets-18.26%

Miscellaneous

Outstanding Shares41,726,000
Market Cap$469.42 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.49 out of 5 stars

Medical Sector

522nd out of 1,972 stocks

Biological Products, Except Diagnostic Industry

73rd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$11.25
-0.18 (-1.57 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FUSN News and Ratings via Email

Sign-up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fusion Pharmaceuticals (NASDAQ:FUSN) Frequently Asked Questions

Is Fusion Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fusion Pharmaceuticals stock.
View analyst ratings for Fusion Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Fusion Pharmaceuticals?

Wall Street analysts have given Fusion Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fusion Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Fusion Pharmaceuticals' next earnings date?

Fusion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Fusion Pharmaceuticals.

How were Fusion Pharmaceuticals' earnings last quarter?

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) posted its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.24) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.02.
View Fusion Pharmaceuticals' earnings history.

What price target have analysts set for FUSN?

5 Wall Street analysts have issued 1-year price targets for Fusion Pharmaceuticals' shares. Their forecasts range from $23.00 to $25.00. On average, they anticipate Fusion Pharmaceuticals' stock price to reach $24.33 in the next twelve months. This suggests a possible upside of 116.3% from the stock's current price.
View analysts' price targets for Fusion Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Fusion Pharmaceuticals' key executives?

Fusion Pharmaceuticals' management team includes the following people:
  • Dr. John F. Valliant, Founder, CEO & Director (Age 51, Pay $564.46k)
  • Mr. John J. Crowley CPA, Chief Financial Officer (Age 47, Pay $424.22k)
  • Dr. Eric Burak, Chief Scientific Officer (Age 56, Pay $384.16k)
  • Ms. Lynn Wick, Exec. Director of Fin. & Operations
  • Ms. Amanda Cray, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Maria D. Stahl, Chief Legal Officer (Age 50)
  • Dr. Marc Schwabish, SVP of Bus. Devel. and US Operations
  • Dr. James J. O'Leary, Chief Medical Officer (Age 56)

Who are some of Fusion Pharmaceuticals' key competitors?

Some companies that are related to Fusion Pharmaceuticals include Scholar Rock (SRRK), C4 Therapeutics (CCCC), Translate Bio (TBIO), Ocugen (OCGN), Replimune Group (REPL), Sangamo Therapeutics (SGMO), Krystal Biotech (KRYS), REGENXBIO (RGNX), Forma Therapeutics (FMTX), Alector (ALEC), Atara Biotherapeutics (ATRA), Immunovant (IMVT), Vaxcyte (PCVX), Coherus BioSciences (CHRS) and Cortexyme (CRTX).
View all of FUSN's competitors.

What other stocks do shareholders of Fusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK).

When did Fusion Pharmaceuticals IPO?

(FUSN) raised $126 million in an IPO on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Fusion Pharmaceuticals' stock symbol?

Fusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "FUSN."

Who are Fusion Pharmaceuticals' major shareholders?

Fusion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Pivotal bioVenture Partners Investment Advisor LLC (3.83%), BlackRock Inc. (1.99%), Federated Hermes Inc. (1.26%), Clough Capital Partners L P (0.96%), Victory Capital Management Inc. (0.43%) and Norges Bank (0.12%). Company insiders that own Fusion Pharmaceuticals stock include Adams Street Partners Llc and Johnson & Johnson.
View institutional ownership trends for Fusion Pharmaceuticals.

Which major investors are selling Fusion Pharmaceuticals stock?

FUSN stock was sold by a variety of institutional investors in the last quarter, including Caas Capital Management LP, and Clough Capital Partners L P.
View insider buying and selling activity for Fusion Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Fusion Pharmaceuticals stock?

FUSN stock was bought by a variety of institutional investors in the last quarter, including Pivotal bioVenture Partners Investment Advisor LLC, BlackRock Inc., Norges Bank, Victory Capital Management Inc., and Federated Hermes Inc..
View insider buying and selling activity for Fusion Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Fusion Pharmaceuticals?

Shares of FUSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fusion Pharmaceuticals' stock price today?

One share of FUSN stock can currently be purchased for approximately $11.25.

How much money does Fusion Pharmaceuticals make?

Fusion Pharmaceuticals has a market capitalization of $469.42 million.

How many employees does Fusion Pharmaceuticals have?

Fusion Pharmaceuticals employs 37 workers across the globe.

What is Fusion Pharmaceuticals' official website?

The official website for Fusion Pharmaceuticals is fusionpharma.com.

Where are Fusion Pharmaceuticals' headquarters?

Fusion Pharmaceuticals is headquartered at 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6.

How can I contact Fusion Pharmaceuticals?

Fusion Pharmaceuticals' mailing address is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. The company can be reached via phone at 289-799-0891 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.